People living in Middle and Low Income Countries (MLICs) do not get access to innovative treatments and new treatments meeting MLIC requirements do not come to market. These issues should be addressed through a demand-side approach— better payer policy in MLICs, supported by international actors, to speed development and dissemination. An Innovation Uptake Institute (IUI) can serve as an honest broker between country payers and suppliers.
TB kills 1.6m people annually - the world’s deadliest infectious disease. The Market-Driven, Value-Based Advance Commitment (MVAC), creates and guarantees a market for better TB treatment. The final “blueprint” has four pillars: HTA to inform countries’ value-based purchase commitments; commitment guarantees underwritten by a development bank; industrial policy alignment; and a governance structure credible to MIC payers and industry.
Adrian Towse presented at the Monash Malaysia Health Economics Forum 2019 on three related topics: health system financing in Malaysia; pharmaceutical price regulation and competition in Malaysia; and the potential for using real world evidence to improve the efficiency of the Malaysian health system.
Market-Driven, Value-Based Advanced Commitment (MVAC) is a new mechanism to help re-direct private-sector R&D investments where they’re needed most. We propose to use MVAC to encourage investments in tuberculosis (TB), which affects 10 million people worldwide. In this blog post, we reflect on the first round of feedback on our consultation draft on MVAC.
A new OHE Research Paper reviews a recent report on cancer pricing published by the World Health Organization. The authors argue that the report fails to promote mechanisms that are key to efficient pricing and use of cancer medicines. The Research Paper outlines some for addressing these shortcomings.
Transparency as a principle of good governance is not the same as transparency for improving access by lowering prices. In fact, the former often carries an opportunity cost on the latter. Developing country markets are, however, dominated by generic products and encouraging competition through sharing prices makes sense if capacities are there to use the data to inform procurement decisions and protect against collusion.
Report does not recommend price transparency for on-patent medicines, but buyers should share multi-source product price data among themselves. Transparency of the procurement process encourages bidders. In many cases, referencing processes and institutions may be a safer bet than trying to copy each other’s prices.
Innovation is a critical tool in the global fight against tuberculosis (TB), an infectious disease that primarily affects the poor and vulnerable and ranks among the top 10 causes of death in the world. The Center for Global Development and the Office of Health Economics are proposing a new innovation model to bring better TB drugs to market. We call it the “Market-Driven, Value-Based Advance Commitment,” or MVAC for short.
The Center for Global Development and the Office of Health Economics are working on a new approach to drive the next generation of investment for better tuberculosis treatment. Our market-focused approach puts Brazil, Russia, India, China, and South Africa (the BRICS) governments in the driver’s seat—empowering them to send a powerful signal to private-sector pharmaceutical companies about the innovation they value and at the kind of price they are willing to consider.